Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$57.00 USD

57.00
907,612

-18.77 (-24.77%)

Updated Aug 7, 2025 10:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Varian (VAR) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Varian's (VAR) fiscal first-quarter earnings are likely to reflect strength in Halcyon platform.

Zacks Equity Research

Haemonetics (HAE) Hits New 52-Week High: What's Driving It?

by Zacks Equity Research

Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.

Zacks Equity Research

What's in Store for Intuitive Surgical's (ISRG) Q4 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) fourth-quarter earnings are likely to reflect solid performance at Instruments & Accessories segment.

Zacks Equity Research

Haemonetics (HAE) Up 14.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Haemonetics (HAE) New Products Aid, Plasma Sales Remain Tepid

by Zacks Equity Research

Haemonetics (HAE) invests in clinical trials that build evidence for its hemostasis management products.

Zacks Equity Research

Haemonetics (HAE) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) second-quarter fiscal 2021 results reflect impressive performance by Hospital segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 24.00% and 3.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Haemonetics (HAE) Q2 Earnings Expected to Decline

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Haemonetics (HAE) Up 18.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

Haemonetics (HAE) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 12.20% and 1.35%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline

by Zacks Equity Research

Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Hold on to Haemonetics Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Haemonetics (HAE) on sustained underlying product demand and geographical expansion.

Zacks Equity Research

Haemonetics (HAE) Inks Deal With GVS for Blood Filter Supply

by Zacks Equity Research

Haemonetics (HAE) inks deal to enhance operations and provide high quality products through an asset-lite approach in its blood filters operations.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Lag Estimates, Margins Expand

by Zacks Equity Research

Haemonetics' (HAE) fourth-quarter fiscal 2020 results reflect strong performance by Plasma segment despite dismal overall performance during the coronavirus-led crisis.

Zacks Equity Research

How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?

by Zacks Equity Research

Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.

Zacks Equity Research

Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.

Zacks Equity Research

What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.

Zacks Equity Research

What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.

Zacks Equity Research

OPKO Health (OPK) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.

Zacks Equity Research

Why Earnings Season Could Be Great for Haemonetics (HAE)

by Zacks Equity Research

Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.

Zacks Equity Research

T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.

Zacks Equity Research

Haemonetics (HAE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.